Compare FMC Corp (FMC) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Smith & Nephew plc — how do they compare? FMC Corp trades at $8.35 (market cap $1.39B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 8× FMC Corp's market cap, and FMC Corp pays the higher dividend (3.59%). Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and Smith & Nephew plc for 121 Days on average.
| FMC | SNN | |
|---|---|---|
Market Cap | $1.39B | $11.10B |
Volume | 4,145,979 | 1,051,703 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $37.17 |
52-Week Low | $8.44 | $26.42 |
Typical Hold Time | 68 Days | 121 Days |
Enterprise Value | $5.19B | $14.13B |
Dividend Yield | 3.59% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $8.92, down 1.87% on the day, with a bearish technical outlook and mixed fundamentals. The stock shows weak profitability with a net income margin of -84.83% and negative ROE of -91.47% for 2025, though recent quarterly EPS beats offer some optimism. Analyst consensus is divided with a near-even split between Buy and Hold ratings, and a $14.60 price target suggests significant upside from current levels. Recent news highlights regulatory progress for rimisoxafen in Brazil and a minority equity investment from Tessenderlo Group.
The outlook for FMC hinges on successful deleveraging and product approvals, but high debt and cyclical industry pressures pose substantial risks. While valuation ratios like P/S of 0.34 appear attractive, persistent negative margins and volatile cash flows warrant caution. The stock presents a speculative opportunity for investors betting on a turnaround, but near-term headwinds in the agricultural sector may limit upside.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
